Fabupharm ordered to recall oil liquid products
The Namibia Medicines Regulatory Council (NMRC) has instructed Fabupharm Namibia (Pty) Ltd to immediately recall all oral liquid products and halt manufacturing from its affected production line.
The directive follows a routine inspection conducted on 2 June 2025, which revealed deficiencies in good manufacturing practices within Fabupharm’s oral liquid dosage section.
The inspection prompted the need for corrective and preventative measures before production could resume.
In a media statement released yesterday, the Registrar of Medicines confirmed that Fabupharm Namibia has been instructed to cease manufacturing on the affected liquid line until all standard requirements are fully corrected and all highlighted issues are resolved.
The NMRC reaffirmed its commitment to ensuring that medicines available in Namibia are safe, effective, and of assured quality.
The Council indicated that further updates will be communicated in due course.
The directive follows a routine inspection conducted on 2 June 2025, which revealed deficiencies in good manufacturing practices within Fabupharm’s oral liquid dosage section.
The inspection prompted the need for corrective and preventative measures before production could resume.
In a media statement released yesterday, the Registrar of Medicines confirmed that Fabupharm Namibia has been instructed to cease manufacturing on the affected liquid line until all standard requirements are fully corrected and all highlighted issues are resolved.
The NMRC reaffirmed its commitment to ensuring that medicines available in Namibia are safe, effective, and of assured quality.
The Council indicated that further updates will be communicated in due course.
Comments
Namibian Sun
No comments have been left on this article